{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":9514,"total_is_capped":false,"direct_labels_cover":106,"predictions_cover":9514,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"11ee7dc1d95b","filters":{"venue":"Journal of Clinical Oncology"}},"results":[{"id":"W2133201432","doi":"10.1200/jco.2006.09.2403","title":"Revised Response Criteria for Malignant Lymphoma","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4448,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Medical physics; Harmonization; Lymphoma; Positron emission tomography; Clinical trial; Oncology; Internal medicine; Nuclear medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1830828747671805,"gpt":0.5290861835862772,"spread":0.3460033088190968,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01422156,0.000121136,0.001322309,0.0001239804,0.00004633707,0.000008371117,0.0001044544,0.0003245791,0.0001249238],"category_scores_gemma":[0.010908,0.00007619528,0.0007779118,0.00008556961,0.000115234,0.00005624002,0.00002425593,0.0001578716,0.00002436581],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003209345,"about_ca_system_score_gemma":0.001521919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004266474,"about_ca_topic_score_gemma":0.000004433834,"domain_scores_codex":[0.9964332,0.0004222936,0.002462778,0.0001623648,0.0002463851,0.0002729631],"domain_scores_gemma":[0.9879258,0.009604478,0.001248628,0.0001947478,0.0005356601,0.000490648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1547112,0.007330968,0.06245675,0.00005386599,0.0007026815,0.005704816,0.0001010554,3.56788e-7,0.001799817,0.0005829858,0.04771424,0.7188413],"study_design_scores_gemma":[0.02086576,0.01982033,0.5403985,0.000120025,0.0003898151,0.000917596,0.00005556319,0.000009048169,0.001053335,0.0002555153,0.4160561,0.0000584194],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807442,0.0007096702,0.0005589846,0.01404681,0.00166259,0.0003378939,0.000004813805,0.000009040019,0.001925963],"genre_scores_gemma":[0.9757976,0.0003553906,0.01582222,0.005799468,0.001705279,0.00000663612,0.000001976228,0.00001590067,0.0004955137],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7187829,"threshold_uncertainty_score":0.9974235,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137853125","doi":"10.1200/jco.2009.25.6529","title":"American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4267,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Oncology; Estrogen receptor; Guideline; Internal medicine; Progesterone receptor; Cancer; Estrogen; Immunohistochemistry; Gynecology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1044654445549377,"gpt":0.4879802130540102,"spread":0.3835147684990725,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003404209,0.000184827,0.001981257,0.00005972757,0.00003174711,0.000001353389,0.0002638749,0.0003754073,0.000009760822],"category_scores_gemma":[0.003274448,0.0001491973,0.0005175357,0.0002101201,0.002376887,0.00001011549,0.0001802194,0.0006090896,1.018794e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006722041,"about_ca_system_score_gemma":0.001653236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003387775,"about_ca_topic_score_gemma":0.000293365,"domain_scores_codex":[0.9948829,0.0003748163,0.004033532,0.0003194029,0.0001501738,0.0002391976],"domain_scores_gemma":[0.9909925,0.001822445,0.005764322,0.0002358866,0.001031689,0.0001531469],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002997467,0.001986729,0.5841122,0.00003286534,0.0005308464,0.000003371688,0.00006186512,0.000006380851,0.0378149,0.00001458303,0.006420092,0.3660187],"study_design_scores_gemma":[0.01500235,0.02497526,0.8488719,0.0001914225,0.0007313594,0.0003361797,0.001651339,0.0001300779,0.009862926,0.0001758643,0.09766392,0.000407377],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860396,0.0003227259,0.0001182662,0.01221965,0.0006677001,0.0002547828,0.0003315038,0.000002775295,0.00004293683],"genre_scores_gemma":[0.8464482,0.001439453,0.1508996,0.0004939849,0.0006377188,0.00003171208,0.00001940491,0.00001912041,0.00001078425],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3656113,"threshold_uncertainty_score":0.8757738,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158134441","doi":"10.1200/jco.2006.07.9525","title":"Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3859,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Gemcitabine; Erlotinib; Medicine; Internal medicine; Pancreatic cancer; Erlotinib Hydrochloride; Oncology; Hazard ratio; Adverse effect; Placebo; Clinical endpoint; Clinical trial; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1918460886647593,"gpt":0.5307549424111981,"spread":0.3389088537464388,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02207563,0.000264837,0.00594495,0.0002294809,0.00006618838,0.000003674724,0.0003922333,0.0003951344,0.0001852582],"category_scores_gemma":[0.01708724,0.0001393375,0.0004383394,0.0006201845,0.001133785,0.0001464089,0.00007600649,0.001516165,3.433752e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001004669,"about_ca_system_score_gemma":0.02693699,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.02019305,"about_ca_topic_score_gemma":0.2416714,"domain_scores_codex":[0.9876862,0.001675321,0.007968129,0.0003319166,0.001828419,0.0005099968],"domain_scores_gemma":[0.9797404,0.01026075,0.00683861,0.0002946297,0.002319579,0.00054605],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4899908,0.005494729,0.485451,0.0000693579,0.001322572,0.00009491313,0.00007185235,0.0001817975,0.00003042494,0.00004629978,0.001095213,0.01615104],"study_design_scores_gemma":[0.407479,0.02329347,0.5636791,0.0005423991,0.0009696356,0.00001965223,0.0000751813,0.000197762,0.00001875689,0.0000279996,0.003591018,0.000105985],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919807,0.0003286014,0.0001746345,0.002784062,0.001737556,0.002081441,0.00006617075,0.000004033304,0.0008427994],"genre_scores_gemma":[0.994629,0.0005472848,0.002550357,0.0008649604,0.001135626,0.00004612674,0.00001269775,0.00002287628,0.0001910374],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2214783,"threshold_uncertainty_score":0.9911922,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2143743735","doi":"10.1200/jco.2007.14.9930","title":"Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Bevacizumab; Medicine; Oxaliplatin; FOLFOX; Folinic acid; Internal medicine; Colorectal cancer; Oncology; Capecitabine; Clinical endpoint; Chemotherapy; Placebo; Hazard ratio; Progression-free survival; Surgery; Randomized controlled trial; Cancer; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1003262096290122,"gpt":0.4668804551886769,"spread":0.3665542455596647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002808337,0.0002261233,0.003339486,0.000286936,0.00006611537,0.000005348592,0.00009952614,0.0001238547,0.0001844092],"category_scores_gemma":[0.001021496,0.0001323439,0.0003481318,0.0003948616,0.0003203796,0.00007802239,0.00001270611,0.0006461031,0.000001520365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00046775,"about_ca_system_score_gemma":0.002112714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007931033,"about_ca_topic_score_gemma":0.004375896,"domain_scores_codex":[0.9959361,0.0007750411,0.002351102,0.0002396651,0.0004640964,0.0002340106],"domain_scores_gemma":[0.9944037,0.003578772,0.00138338,0.0001087347,0.0003702618,0.0001551568],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7567224,0.02815787,0.1437737,0.00001069503,0.001226462,0.002554791,0.002226249,0.0001973864,0.00001776878,0.000005941728,0.00007290138,0.06503387],"study_design_scores_gemma":[0.7232818,0.09068837,0.183564,0.00009112885,0.0002760773,0.0001363063,0.0003486132,0.0008438114,0.00006469574,0.00007941967,0.0005225685,0.0001032308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894973,0.001072731,0.0000287632,0.006736963,0.000280019,0.002021522,0.000002511772,0.000008942112,0.0003512716],"genre_scores_gemma":[0.9935449,0.004396458,0.0004809159,0.001158344,0.0001390117,0.0001948652,0.000003206598,0.00001997953,0.00006231182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06493064,"threshold_uncertainty_score":0.5396829,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2984359187","doi":"10.1200/jco.19.02105","title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":2963,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Pembrolizumab; Medicine; Microsatellite instability; Cancer; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; DNA mismatch repair; Phases of clinical research; Gastroenterology; Immunotherapy; Toxicity; Clinical trial; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.05014804818147979,"gpt":0.4084384987829472,"spread":0.3582904506014675,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003700852,0.0002898436,0.002301787,0.0001353965,0.00005176086,0.00000864569,0.0004497922,0.0004038575,0.0002131111],"category_scores_gemma":[0.004012291,0.0001652881,0.0004819109,0.0004384656,0.0003994167,0.00008133762,0.0002178841,0.001591126,0.00001084706],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006801601,"about_ca_system_score_gemma":0.002819044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009471729,"about_ca_topic_score_gemma":0.000949336,"domain_scores_codex":[0.9929946,0.0009657486,0.004201877,0.0005489761,0.0008981131,0.0003906832],"domain_scores_gemma":[0.9895917,0.005573061,0.002853682,0.0007330751,0.0009717714,0.0002767699],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2682187,0.0221705,0.6797904,0.00002125508,0.0004554187,0.00007246486,0.002056085,0.0003121306,0.0001940083,0.000002361149,0.0004281314,0.02627855],"study_design_scores_gemma":[0.1083497,0.1363562,0.7496374,0.0001945272,0.0003741245,0.000008612674,0.0003723709,0.00004814737,0.000226528,0.00002174472,0.004279037,0.0001316004],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933583,0.000266653,0.000002500693,0.001537502,0.002451107,0.001864433,0.00009989101,0.00001387785,0.0004057337],"genre_scores_gemma":[0.9978804,0.0001175798,0.0008676644,0.0005904976,0.0004134304,0.00001078491,0.00001491681,0.0000322398,0.00007250044],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.159869,"threshold_uncertainty_score":0.6912737,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2104504726","doi":"10.1200/jco.2007.13.9030","title":"Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":2670,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"American Society of Clinical Oncology; Les Laboratories Pierre Fabre; Sanofi; GlaxoSmithKline; Eli Lilly and Company","keywords":"Medicine; Vinorelbine; Internal medicine; Vinca; Chemotherapy; Etoposide; Hazard ratio; Vinca alkaloid; Cisplatin; Lung cancer; Oncology; Stage (stratigraphy); Vindesine; Clinical trial; Confidence interval; Pharmacology; Cyclophosphamide; Vincristine","retraction":null,"screen_n_in":null,"score":{"opus":0.09634526887575641,"gpt":0.4933364237251135,"spread":0.3969911548493571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004043936,0.0001239165,0.001403666,0.0000945709,0.0001040667,0.000007706309,0.0001253517,0.0001970377,0.000579152],"category_scores_gemma":[0.00198097,0.00006421642,0.0006378833,0.0006443684,0.0001995527,0.00007374695,0.00002713325,0.0005243658,0.00001339285],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005461228,"about_ca_system_score_gemma":0.00195467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003052996,"about_ca_topic_score_gemma":0.0001366611,"domain_scores_codex":[0.996356,0.0009337307,0.001653245,0.0001839146,0.0007104058,0.0001627033],"domain_scores_gemma":[0.9940189,0.002916643,0.001550671,0.0002270996,0.001038443,0.0002483156],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003854607,0.004503174,0.5879244,0.00001456651,0.01826908,0.001029279,0.0007403329,0.0002725642,0.00003622847,0.0001278243,0.301977,0.08125094],"study_design_scores_gemma":[0.0179608,0.01089006,0.8608953,0.00006571517,0.03005998,0.0003448946,0.0003855973,0.003087372,0.00005778959,0.0001100051,0.07602202,0.0001205],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9410008,0.008737335,0.0002472992,0.04415539,0.0007258152,0.0005190164,0.00001299139,0.000007011527,0.004594394],"genre_scores_gemma":[0.9920347,0.002547807,0.0009404092,0.00339382,0.0006803533,0.00002748239,0.00001192961,0.000008739306,0.0003547627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2729709,"threshold_uncertainty_score":0.6341308,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2118558111","doi":"10.1200/jco.2012.45.2722","title":"Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":2658,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of New Brunswick","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Underweight; Body mass index; Overweight; Obesity paradox; Cachexia; Weight loss; Internal medicine; Cancer; Obesity; Skeletal muscle; Lung cancer; Univariate analysis; Multivariate analysis","retraction":null,"screen_n_in":null,"score":{"opus":0.1179012815893561,"gpt":0.4682270623116528,"spread":0.3503257807222967,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002241435,0.0000965382,0.001018171,0.0001737485,0.00001859111,0.000005067797,0.0001706953,0.0003286946,0.0006789042],"category_scores_gemma":[0.001349034,0.0000614906,0.0002714994,0.0001677945,0.0001643343,0.00008491043,0.00002771313,0.001167866,0.000009264399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001247629,"about_ca_system_score_gemma":0.0008887759,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003754417,"about_ca_topic_score_gemma":0.0001472886,"domain_scores_codex":[0.9964675,0.0004843064,0.002220267,0.0001225643,0.0004987443,0.0002066529],"domain_scores_gemma":[0.9964609,0.001263332,0.001506494,0.0001500617,0.0004541487,0.0001650202],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002914071,0.001852501,0.9790798,0.000192166,0.00007524269,0.0001570988,0.000400132,0.000002311264,0.001378742,0.0000366963,0.001470309,0.01506353],"study_design_scores_gemma":[0.004569856,0.003189142,0.9818613,0.0002894858,0.00008986391,0.00006050715,0.0002940175,0.0000970927,0.00008350281,0.0007209578,0.008694421,0.00004988662],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840681,0.0003495064,0.0002180802,0.01385085,0.0005289787,0.0004433696,0.000004604434,0.000003069848,0.0005334601],"genre_scores_gemma":[0.9946709,0.0005741073,0.0006008357,0.003719585,0.0003724066,0.00000817971,0.000001732928,0.000008939653,0.00004328051],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01501364,"threshold_uncertainty_score":0.7433525,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2134667653","doi":"10.1200/jco.2004.08.163","title":"Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2433,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Neutropenia; Internal medicine; Lung cancer; Febrile neutropenia; Chemotherapy; Regimen; Dexamethasone; Chemotherapy regimen; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.04615425508884495,"gpt":0.4591494644487017,"spread":0.4129952093598567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001051495,0.0001794287,0.002421539,0.0001696853,0.00002284824,0.000005158924,0.00009388992,0.0001897106,0.0000915265],"category_scores_gemma":[0.0003426865,0.00009518034,0.0003518582,0.0002582961,0.0001909578,0.00008287624,0.000008470229,0.0004133953,6.777243e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004222906,"about_ca_system_score_gemma":0.003233135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00038064,"about_ca_topic_score_gemma":0.0002439179,"domain_scores_codex":[0.9971646,0.0002084823,0.001892184,0.0001851159,0.0003387604,0.0002108456],"domain_scores_gemma":[0.9961243,0.0008466337,0.002109214,0.0001592677,0.0005312697,0.0002293182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9463388,0.01282364,0.02525796,0.00003585609,0.002170798,0.0001199153,0.0003956804,0.000147381,0.000008424442,0.000005169323,0.00008796329,0.01260836],"study_design_scores_gemma":[0.9316074,0.05310173,0.01059268,0.0002924645,0.003769055,0.000005701278,0.0000530584,0.00002760351,0.0001183547,0.000007579977,0.0003341824,0.00009020005],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944122,0.0003296216,0.0001643846,0.001274907,0.0004033178,0.002057663,0.000005549364,0.000005462451,0.001346844],"genre_scores_gemma":[0.9959084,0.0007866677,0.002392752,0.0003744359,0.0002827246,0.00005651735,0.00001018772,0.00002323203,0.0001651274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04027809,"threshold_uncertainty_score":0.5735443,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2116760308","doi":"10.1200/jco.2009.25.9820","title":"Metastatic Behavior of Breast Cancer Subtypes","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2284,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Basal (medicine); Internal medicine; Oncology; Cancer; Pathology; Lung cancer; Lung; Metastasis; Stage (stratigraphy); Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.06226160108180336,"gpt":0.4550223279959653,"spread":0.392760726914162,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008049377,0.000102471,0.0006628333,0.00003706179,0.00002301913,0.000002771382,0.0001905643,0.0001871847,0.0001439977],"category_scores_gemma":[0.00049668,0.00007188594,0.0003271255,0.00005083711,0.0002845451,0.000004941282,0.00006601686,0.0003434005,0.000003126009],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001365655,"about_ca_system_score_gemma":0.0007401727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006575212,"about_ca_topic_score_gemma":0.0004755559,"domain_scores_codex":[0.9984061,0.0001274716,0.001047913,0.0001346527,0.0001468111,0.0001370424],"domain_scores_gemma":[0.9979088,0.0002080752,0.001143128,0.000164125,0.0004503489,0.0001254862],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002117136,0.002232484,0.7144217,0.00001829679,0.001062379,0.00008013102,0.00004218363,0.000008630956,0.08105303,0.0001079651,0.004149503,0.1947066],"study_design_scores_gemma":[0.002728862,0.001583104,0.9594917,0.00001270215,0.0005453246,0.0003871208,0.00004899048,0.000001246863,0.007180354,0.00007966954,0.02785136,0.00008958641],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954417,0.0005512856,0.00002931031,0.001856526,0.001636774,0.00006286184,0.00004472859,0.000001607164,0.0003752309],"genre_scores_gemma":[0.9955738,0.0006812164,0.002315563,0.0003296765,0.001000162,0.000008648593,0.000002730305,0.00001126041,0.00007700182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.24507,"threshold_uncertainty_score":0.2931423,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099088585","doi":"10.1200/jco.2008.20.1293","title":"Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2189,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Pfizer Canada; Genentech; GlaxoSmithKline; American Society of Clinical Oncology; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Hazard ratio; Discontinuation; Alpha interferon; Adverse effect; Clinical endpoint; Gastroenterology; Log-rank test; Progression-free survival; Oncology; Urology; Proportional hazards model; Randomized controlled trial; Confidence interval; Interferon; Overall survival; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.1019284234891843,"gpt":0.387397130270231,"spread":0.2854687067810467,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001528743,0.0002156137,0.00164204,0.0001808292,0.0000273663,0.00001220251,0.0001069507,0.000139403,0.00001393904],"category_scores_gemma":[0.0003679104,0.0001255705,0.0001532643,0.0001267949,0.0001408633,0.0001117552,0.00002054397,0.0006156361,0.000001386394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001880098,"about_ca_system_score_gemma":0.0006278171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000350907,"about_ca_topic_score_gemma":0.0001324935,"domain_scores_codex":[0.9967151,0.0004114947,0.001933227,0.0002692213,0.0003767963,0.000294162],"domain_scores_gemma":[0.9962416,0.001256617,0.001350234,0.0001919621,0.0005795083,0.0003801118],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4589908,0.009434829,0.5069016,0.00007919635,0.0005341464,0.002319429,0.0003591686,0.0001140267,0.0001608457,0.00006274344,0.003081614,0.01796165],"study_design_scores_gemma":[0.07816819,0.1215314,0.7970845,0.0001058682,0.0005100859,0.000100509,0.00009108274,0.00007528416,0.0001958743,0.00006147391,0.001961788,0.0001140353],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947869,0.00009036394,0.00008734361,0.002221924,0.0001422176,0.0005943442,0.00002370504,0.000005436068,0.002047826],"genre_scores_gemma":[0.9915873,0.00001729161,0.007454969,0.0005529053,0.0001425104,0.000003424357,0.00007915462,0.00001716395,0.0001452485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3808226,"threshold_uncertainty_score":0.5120615,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2099752220","doi":"10.1200/jco.2008.21.4809","title":"Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":2130,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Internal medicine; Bevacizumab; Sorafenib; Proportional hazards model; Cohort; Adverse effect; Oncology; Vascular endothelial growth factor; Cancer; Gastroenterology; Hepatocellular carcinoma; Chemotherapy; VEGF receptors","retraction":null,"screen_n_in":null,"score":{"opus":0.07369899872305304,"gpt":0.3582692181119489,"spread":0.2845702193888959,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001184984,0.000455983,0.002432666,0.0002794367,0.00005441655,0.00002217341,0.0002199273,0.0002224574,0.00004361083],"category_scores_gemma":[0.002737939,0.0002533408,0.0005212167,0.000209399,0.00007942964,0.0001904496,0.00003088091,0.0008208487,0.000003573975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004296512,"about_ca_system_score_gemma":0.0007268643,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002708506,"about_ca_topic_score_gemma":0.000221792,"domain_scores_codex":[0.9940954,0.001021821,0.002786796,0.0005687625,0.0009617065,0.0005654492],"domain_scores_gemma":[0.9925553,0.00367191,0.001948249,0.000351218,0.0009176803,0.0005556946],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06877743,0.02417987,0.9030361,0.00001976893,0.001070256,0.001499038,0.0007439583,0.00002577924,0.00004984829,9.524935e-7,0.00006768166,0.0005293277],"study_design_scores_gemma":[0.1329947,0.0960781,0.7680778,0.00008645887,0.001839409,0.000004182816,0.000276701,0.00006554793,0.0002479079,0.00001083019,0.0001278774,0.000190521],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963731,0.00005837377,0.0001102646,0.0001826638,0.0002462736,0.002631238,0.0002799777,0.00001522386,0.0001029026],"genre_scores_gemma":[0.9968079,0.00001254232,0.00240161,0.000252282,0.0002252831,0.00001790437,0.000186377,0.00004708295,0.00004903361],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1349583,"threshold_uncertainty_score":0.9999919,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2103257412","doi":"10.1200/jco.2005.07.757","title":"Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vinblastine; Gemcitabine; Internal medicine; Transitional cell carcinoma; Hazard ratio; Cisplatin; Bladder cancer; Urology; Oncology; Methotrexate; Chemotherapy; Doxorubicin; Antimetabolite; Progression-free survival; Gastroenterology; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.08192046514609955,"gpt":0.4237490158951968,"spread":0.3418285507490972,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004316886,0.0003890793,0.00563351,0.0003206978,0.00004250218,0.00001357036,0.0002313663,0.0003756412,0.0002105778],"category_scores_gemma":[0.002430305,0.0002222455,0.0005373771,0.0003856854,0.0004534547,0.0002092658,0.00006353101,0.001188515,0.0000045269],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005033835,"about_ca_system_score_gemma":0.002956778,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003635754,"about_ca_topic_score_gemma":0.002537508,"domain_scores_codex":[0.9920939,0.001127596,0.004894588,0.0004206659,0.001006627,0.0004566649],"domain_scores_gemma":[0.9899384,0.004171566,0.00410124,0.0003219161,0.001041457,0.0004254585],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7947931,0.002356828,0.1873783,0.0000416278,0.001754045,0.0001856618,0.0002303236,0.001262169,0.00001165468,0.000006929673,0.0002010419,0.01177836],"study_design_scores_gemma":[0.6875517,0.01718376,0.2923592,0.0004934956,0.001622022,0.00003062429,0.00002344525,0.0003322453,0.00006628237,0.000006639565,0.0001698765,0.000160711],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922132,0.0002857507,0.0003386549,0.001348793,0.000882586,0.001706581,0.00002692611,0.00001323197,0.0031842],"genre_scores_gemma":[0.9925693,0.0002221709,0.004952338,0.000374902,0.001312104,0.00004174825,0.00002110941,0.00004879211,0.0004575963],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1072414,"threshold_uncertainty_score":0.9062907,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2990602950","doi":"10.1200/jco.19.01307","title":"Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1819,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Pembrolizumab; Placebo; Hazard ratio; Internal medicine; Sorafenib; Interim analysis; Adverse effect; Population; Randomized controlled trial; Intention-to-treat analysis; Hepatocellular carcinoma; Subgroup analysis; Surgery; Gastroenterology; Confidence interval; Cancer; Immunotherapy; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1234301453155467,"gpt":0.4015304858931631,"spread":0.2781003405776164,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004509248,0.0003755119,0.004492629,0.0005286865,0.00002710509,0.0000166743,0.0002370723,0.0006402436,0.00100513],"category_scores_gemma":[0.0006145315,0.0002379902,0.0009813989,0.0004032616,0.0001950951,0.0002532421,0.00004372511,0.001502511,0.00005510644],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002829153,"about_ca_system_score_gemma":0.002032063,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007795037,"about_ca_topic_score_gemma":0.00004930125,"domain_scores_codex":[0.9932193,0.001123513,0.004057764,0.0004475044,0.0006667204,0.0004852366],"domain_scores_gemma":[0.9945769,0.002013534,0.002098855,0.0003826853,0.0004718965,0.0004561065],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5373001,0.006570712,0.4414122,0.00001647788,0.0002393258,0.0009859481,0.0001237513,0.000003561692,0.00001376017,0.00001575986,0.00001703751,0.01330136],"study_design_scores_gemma":[0.8894306,0.07901433,0.02790324,0.0001269848,0.0003068075,0.00006029303,0.00004158542,0.0006670605,0.0002351331,0.00008777357,0.001912446,0.0002137104],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905853,0.0007912428,0.00001246767,0.0008876286,0.000994008,0.005183829,0.000003673034,0.0000111322,0.001530668],"genre_scores_gemma":[0.9974744,0.0003967376,0.0003531143,0.000787123,0.0005123988,0.00009881734,0.00003776605,0.00004747091,0.0002922157],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.413509,"threshold_uncertainty_score":0.9999081,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2910245285","doi":"10.1200/jco.18.00149","title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1716,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Internal medicine; Hazard ratio; Oncology; Tolerability; Clinical endpoint; Chemotherapy regimen; Surgery; Cancer; Confidence interval; Randomized controlled trial; Immunotherapy; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.06235330001325926,"gpt":0.4207660967554982,"spread":0.3584127967422389,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001234685,0.0002086523,0.002218437,0.0003424612,0.0000234059,0.000004754134,0.0001788529,0.000276954,0.001046397],"category_scores_gemma":[0.0001684701,0.0001237587,0.0008853101,0.0005441471,0.0001971503,0.00008308437,0.00001249447,0.0003822944,7.94325e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002417742,"about_ca_system_score_gemma":0.003000902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007450489,"about_ca_topic_score_gemma":0.0001920828,"domain_scores_codex":[0.9965624,0.0001173432,0.00241095,0.0002676988,0.0003888527,0.0002528068],"domain_scores_gemma":[0.994031,0.0007432016,0.003880802,0.0002970159,0.0008973403,0.0001506003],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7264834,0.001247091,0.2294607,0.0003552974,0.006082542,0.00005096097,0.0001418393,0.001272324,0.01565949,0.000001282562,0.0004395106,0.01880558],"study_design_scores_gemma":[0.237349,0.08075658,0.6128643,0.0008317154,0.01146565,0.00004459859,0.000318929,0.009887537,0.03912994,0.000004630272,0.006972005,0.000375071],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961542,0.000264054,0.0007487654,0.001041489,0.0006232134,0.0009131513,0.00003169732,0.000007285986,0.0002160804],"genre_scores_gemma":[0.9933583,0.0002205901,0.004803628,0.0009128539,0.0001941218,0.00002094371,0.00002513931,0.00003254385,0.000431885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4891344,"threshold_uncertainty_score":0.9998668,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2999400187","doi":"10.1200/jco.19.02309","title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1497,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Saskatchewan; Saskatchewan Health Authority","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Breast cancer; Oncology; Estrogen receptor; Cancer; Internal medicine; Progesterone receptor; Gynecology; Estrogen; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.08838685065811515,"gpt":0.424895718177958,"spread":0.3365088675198428,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007484445,0.00013679,0.0006666452,0.0000205725,0.00003041169,0.000007699227,0.0001509961,0.0002074767,0.00002171568],"category_scores_gemma":[0.001011927,0.0001066961,0.0001110917,0.00009308114,0.0001528063,0.000008382361,0.0001478714,0.000304389,0.000003791618],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003894541,"about_ca_system_score_gemma":0.0005839948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005945677,"about_ca_topic_score_gemma":0.00005494126,"domain_scores_codex":[0.997887,0.0001828638,0.001375107,0.0002435396,0.0001198045,0.0001917482],"domain_scores_gemma":[0.9984148,0.000151353,0.0008410718,0.00009164598,0.0002725584,0.0002285696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002569498,0.000407617,0.7424225,0.0000206614,0.0003769075,0.0000835914,0.00005086324,0.00006736319,0.006757555,0.00001703791,0.01240984,0.2348166],"study_design_scores_gemma":[0.01196293,0.006053233,0.6379083,0.0001215079,0.0002679247,0.0005757645,0.0001996964,0.0001428008,0.001733061,0.00007450331,0.3406136,0.0003466098],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9327103,0.003896453,0.00005417067,0.06276616,0.0003017403,0.0001013348,0.00004126659,0.000004525554,0.0001240375],"genre_scores_gemma":[0.9762698,0.003542361,0.01169984,0.006106428,0.002331645,0.000009400525,0.00001036604,0.00002044489,0.000009691522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3282038,"threshold_uncertainty_score":0.4350942,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2966354200","doi":"10.1200/jco.19.01461","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1475,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; BC Cancer Agency","funders":"","keywords":"Medicine; Edoxaban; Rivaroxaban; Apixaban; Cancer; Intensive care medicine; Guideline; Randomized controlled trial; Venous thromboembolism; Cochrane Library; Low molecular weight heparin; Ambulatory; Internal medicine; Warfarin; Heparin; Thrombosis","retraction":null,"screen_n_in":null,"score":{"opus":0.1349317751211059,"gpt":0.5122619900840704,"spread":0.3773302149629645,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00577233,0.0006034144,0.01450126,0.0002928335,0.00004940663,0.00002846291,0.0003137464,0.001260559,0.0001107903],"category_scores_gemma":[0.003433513,0.0003411571,0.001226345,0.0002876956,0.0003079131,0.000205195,0.0001776506,0.002253951,0.00005527815],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007607941,"about_ca_system_score_gemma":0.006260064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00022288,"about_ca_topic_score_gemma":0.0001068,"domain_scores_codex":[0.9882721,0.001571489,0.008234879,0.000700772,0.0007332655,0.0004875262],"domain_scores_gemma":[0.9864454,0.003444734,0.007988037,0.0006011514,0.0009429668,0.000577658],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001310669,0.01857642,0.005097807,0.001671796,0.003893816,0.0007500756,0.00003516863,0.000002837269,2.135729e-9,0.00004621345,0.007928836,0.9606864],"study_design_scores_gemma":[0.01022294,0.0634374,0.04237362,0.005240932,0.01288678,0.0001146022,0.00002481458,0.000001874238,1.214819e-8,0.00001213247,0.8654127,0.0002721492],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.006058916,0.9831393,0.000008428559,0.002777097,0.003264813,0.00307754,0.00003656904,0.00001287267,0.001624426],"genre_scores_gemma":[0.0002326198,0.9893634,0.00479304,0.003063905,0.002248561,0.00005765707,0.00004470245,0.00008972701,0.0001064006],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9604142,"threshold_uncertainty_score":0.999904,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141768150","doi":"10.1200/jco.2004.05.063","title":"American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer","year":2004,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1451,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Internal medicine; Disease; Oncology; Guideline; Colorectal cancer; Chemotherapy; Adjuvant therapy; Clinical trial; Cancer; Adjuvant; Adjuvant chemotherapy; Perforation; Intensive care medicine; Surgery; Breast cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.454633654644825,"gpt":0.6437214622989518,"spread":0.1890878076541268,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.007224507,0.0006111965,0.01628766,0.0002157137,0.0001112806,0.00000694556,0.0005078822,0.0019727,0.0006741751],"category_scores_gemma":[0.003879721,0.0004065831,0.008391111,0.0005231593,0.001075198,0.00007114918,0.0001445316,0.003553413,0.00001313144],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002800332,"about_ca_system_score_gemma":0.02391822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001107262,"about_ca_topic_score_gemma":0.0001308784,"domain_scores_codex":[0.9861624,0.001535784,0.01041337,0.0007106913,0.0006207334,0.0005569847],"domain_scores_gemma":[0.9643641,0.01683592,0.01643017,0.0005030627,0.001011379,0.0008553942],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007903441,0.008619397,0.0004367138,0.002180546,0.00479973,0.0001164749,0.00005696157,0.000004276655,3.249903e-7,0.00005021994,0.02063408,0.9551978],"study_design_scores_gemma":[0.016764,0.1005876,0.001156835,0.006644451,0.004232417,0.0001001493,0.00004988907,0.000009508611,0.000001674234,0.00006485807,0.8701337,0.0002549973],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.004264737,0.9481853,0.0001514614,0.03144551,0.008617907,0.003991393,0.0005816406,0.00004100403,0.002721035],"genre_scores_gemma":[0.0002879223,0.9763265,0.01299859,0.00503734,0.003369599,0.0002137484,0.0000684639,0.0001057252,0.001592165],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9549428,"threshold_uncertainty_score":0.9998386,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974820090","doi":"10.1200/jco.2011.38.0527","title":"Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1420,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Medicine; Karnofsky Performance Status; Lung cancer; Recursive partitioning; Oncology; Internal medicine; Multivariate analysis; Performance status; Brain metastasis; Univariate analysis; Cancer; Univariate; Melanoma; Proportional hazards model; Retrospective cohort study; Metastasis; Multivariate statistics","retraction":null,"screen_n_in":null,"score":{"opus":0.2187776587296088,"gpt":0.4748473178935615,"spread":0.2560696591639527,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004342676,0.0002010122,0.001104461,0.00008120877,0.00009845596,0.00002434173,0.0001314008,0.0001159269,0.00008026797],"category_scores_gemma":[0.004518317,0.00009797964,0.0002347383,0.0001046409,0.0001537637,0.0001353682,0.00004322263,0.0004138942,0.000003772374],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006254078,"about_ca_system_score_gemma":0.0004535536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000008562928,"about_ca_topic_score_gemma":0.00002659737,"domain_scores_codex":[0.9969087,0.0006205023,0.001509848,0.0003045755,0.0003928228,0.0002635082],"domain_scores_gemma":[0.9910457,0.006643958,0.001161865,0.0003111533,0.0004310698,0.0004063232],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009225066,0.01335563,0.8414117,0.00004031493,0.001238836,0.002672165,0.000136988,0.00001413213,0.000005861712,0.001578697,0.01142879,0.1188919],"study_design_scores_gemma":[0.007703402,0.06365807,0.8672654,0.0001144136,0.000685588,0.0001907311,0.00008825415,0.00001526603,0.00002664541,0.0005020695,0.05962496,0.000125211],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901366,0.00006605613,0.0007141536,0.006950395,0.0005110639,0.001305779,0.0000790526,0.0000106103,0.0002262769],"genre_scores_gemma":[0.9702652,0.00006924562,0.02720707,0.001911386,0.0002612869,0.0001304159,0.0000604602,0.00002701065,0.00006794139],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1187667,"threshold_uncertainty_score":0.5409174,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2167494200","doi":"10.1200/jco.2014.59.7351","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1373,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia Hospital","funders":"National Heart, Lung, and Blood Institute; University of North Carolina at Chapel Hill; Wilmot Cancer Institute, University of Rochester Medical Center; Universidad de Granada; McMaster University; School of Medicine, Emory University; Pennsylvania State University; University of Pennsylvania; Penn State Hershey Cancer Institute; University of Rochester; Emory University; Cleveland Clinic; University of Washington; University of Southern California","keywords":"Medicine; Guideline; Cancer; Pulmonary embolism; Deep vein; Intensive care medicine; Randomized controlled trial; Clinical trial; Low molecular weight heparin; Thrombosis; Malignancy; Internal medicine; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.1164542965855454,"gpt":0.4944507079326678,"spread":0.3779964113471224,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01443854,0.0003429057,0.006853453,0.0001478922,0.00004407462,0.00001211246,0.0002735011,0.000698121,0.00005889574],"category_scores_gemma":[0.006341794,0.0002185321,0.0008059668,0.000291931,0.001325538,0.0002359476,0.0001925225,0.001624889,0.00001464848],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005236376,"about_ca_system_score_gemma":0.006384529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001291433,"about_ca_topic_score_gemma":0.0005247903,"domain_scores_codex":[0.9878865,0.002061416,0.008151847,0.0005860872,0.0008283826,0.0004857418],"domain_scores_gemma":[0.9845097,0.003936802,0.007852227,0.0004790383,0.002128354,0.0010939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.008167796,0.03023282,0.3907391,0.00002583597,0.001783263,0.0002199413,0.0002579114,0.00003666397,6.039344e-7,0.00004234979,0.06346495,0.5050288],"study_design_scores_gemma":[0.01934911,0.1150775,0.4858748,0.00007036371,0.001196123,0.00002923068,0.0004785007,0.00005944811,0.000001347952,0.00004967838,0.3776906,0.0001233472],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9668267,0.0009430861,0.00009420444,0.02752089,0.002053355,0.0009822779,0.00001587044,0.00001411249,0.001549488],"genre_scores_gemma":[0.8777012,0.03334196,0.06595284,0.01991258,0.002913833,0.00003222661,0.00001901089,0.00006132099,0.00006498823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5049055,"threshold_uncertainty_score":0.9992483,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2153398041","doi":"10.1200/jco.2009.27.4324","title":"Medulloblastoma Comprises Four Distinct Molecular Variants","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1353,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Deutsche Kinderkrebsstiftung; Pediatric Brain Tumor Foundation; Sontag Foundation; American Brain Tumor Association","keywords":"Medulloblastoma; Medicine; Oncology; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.0885155091889863,"gpt":0.4474748075378588,"spread":0.3589592983488725,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001487913,0.0001265517,0.001179593,0.00009451678,0.00003372221,0.000009680468,0.0001487134,0.0003246276,0.0004428167],"category_scores_gemma":[0.004686345,0.00008105686,0.0005642304,0.00009427004,0.0001707464,0.00005144584,0.00004813221,0.0009885639,0.00006122397],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003941644,"about_ca_system_score_gemma":0.000719572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007869576,"about_ca_topic_score_gemma":0.0000350754,"domain_scores_codex":[0.9975625,0.0001846473,0.00155863,0.0001540971,0.0003391071,0.0002010376],"domain_scores_gemma":[0.9961002,0.001653576,0.001077046,0.000225911,0.0003945426,0.0005486493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002784841,0.01256824,0.58479,0.00003234194,0.001727944,0.02768352,0.00004747581,0.000007495217,0.02666651,0.001827189,0.01645685,0.3254076],"study_design_scores_gemma":[0.0098202,0.008473942,0.8769647,0.00005443086,0.0006826098,0.002318716,0.00001674253,0.0000652864,0.001816016,0.0008159772,0.09888092,0.00009042353],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802381,0.0001148977,0.0001418861,0.01135531,0.002306125,0.0001223006,0.000002500096,0.000009796828,0.005709049],"genre_scores_gemma":[0.991136,0.00005267205,0.006148634,0.001620383,0.0009815915,0.000003170912,0.000001308671,0.00001494722,0.00004131974],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3253171,"threshold_uncertainty_score":0.5610331,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2107283868","doi":"10.1200/jco.2013.50.3870","title":"Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":1290,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Institutes of Health","keywords":"Incidence (geometry); Medicine; Demography; Lung cancer; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1488095144977064,"gpt":0.5240838037066335,"spread":0.3752742892089272,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001554917,0.00009178743,0.001379961,0.0001305222,0.00002974352,0.00000599182,0.00006971994,0.0001552367,0.0001462841],"category_scores_gemma":[0.002183877,0.00006134074,0.0001678718,0.0001402464,0.0002014977,0.0001347607,0.00003539207,0.0005052902,0.000003666338],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002079886,"about_ca_system_score_gemma":0.0008543283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001231534,"about_ca_topic_score_gemma":0.005668264,"domain_scores_codex":[0.998144,0.0001391457,0.001236715,0.0001368261,0.0001303499,0.0002129335],"domain_scores_gemma":[0.9968919,0.002007613,0.0005081766,0.00007169723,0.0002560574,0.0002645564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002051521,0.0002465888,0.3312182,0.00002865183,0.000104339,0.0001172311,0.000185733,0.000002748797,0.0001519286,0.0000327451,0.0257756,0.6400847],"study_design_scores_gemma":[0.007128173,0.00889934,0.9320486,0.0000997336,0.00009883407,0.00008663229,0.0001209688,0.0002048231,0.00003198247,0.0003306554,0.05088152,0.00006879825],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736782,0.0009808069,0.00001167672,0.02248119,0.0007122427,0.0001364154,0.000001598265,0.000003057222,0.001994779],"genre_scores_gemma":[0.9909785,0.001072476,0.003023422,0.003505845,0.0006119857,0.0000153232,6.242294e-7,0.000007660598,0.0007841639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.640016,"threshold_uncertainty_score":0.3163024,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2944301866","doi":"10.1200/jco.19.00201","title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1270,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"London Health Sciences Centre","funders":"National Cancer Institute; Ignyta; University of Texas MD Anderson Cancer Center; Genentech","keywords":"Medicine; Clinical endpoint; Radiation therapy; Lung cancer; Randomized controlled trial; Surgery; Systemic therapy; Progression-free survival; Internal medicine; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1064471531521062,"gpt":0.4624029523308717,"spread":0.3559557991787655,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002349318,0.0002446096,0.002736353,0.0001132079,0.0000627821,0.000008158986,0.0001507884,0.0001479798,0.00006461731],"category_scores_gemma":[0.000843649,0.0001159899,0.0004847292,0.0001633658,0.0003055564,0.000129172,0.000022992,0.0003294709,0.000001287204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004095873,"about_ca_system_score_gemma":0.002780271,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007586949,"about_ca_topic_score_gemma":0.0001459923,"domain_scores_codex":[0.9961058,0.0004364156,0.002513733,0.0003098639,0.0004010124,0.0002331659],"domain_scores_gemma":[0.9905652,0.004237454,0.003152526,0.0002336257,0.00161374,0.0001974438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5925357,0.0374123,0.3233213,0.00009001806,0.002620822,0.00008683627,0.0005917093,0.0001414714,0.00001112757,0.000005226259,0.0003016785,0.04288187],"study_design_scores_gemma":[0.6895117,0.09296405,0.2142995,0.0004173837,0.0009288719,0.000008179347,0.0001027405,0.000991313,0.0002054414,0.00000469411,0.0004630835,0.0001030611],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883633,0.0005889751,0.003027954,0.001386275,0.000711524,0.005803379,0.00007724518,0.000005526695,0.00003580018],"genre_scores_gemma":[0.9894091,0.004373915,0.004341793,0.001159452,0.0001527548,0.0002797337,0.0000326536,0.00002129646,0.0002292664],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1090218,"threshold_uncertainty_score":0.4932081,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3032651552","doi":"10.1200/jco.20.00818","title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1242,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Surrey Place Centre; Nova Scotia Cancer Centre; Health Sciences Centre; McGill University Health Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Positive Living North; London Health Sciences Centre","funders":"","keywords":"Medicine; SABR volatility model; Randomized controlled trial; Clinical endpoint; Radiation therapy; Radiosurgery; Prostate cancer; Internal medicine; Ablative case; Oncology; Quality of life (healthcare); Surgery; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.3547905206584541,"gpt":0.4845785244643184,"spread":0.1297880038058644,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001805095,0.0001965834,0.003316318,0.00007015007,0.00006929724,0.00000540656,0.0001942263,0.0001611185,0.0000740027],"category_scores_gemma":[0.003292993,0.00008369399,0.002076422,0.0002106065,0.0005261935,0.0000524398,0.00002425256,0.0002842062,6.027362e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002040154,"about_ca_system_score_gemma":0.001407807,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004549724,"about_ca_topic_score_gemma":0.00001304094,"domain_scores_codex":[0.9947397,0.001477212,0.003087616,0.0001786519,0.0003383915,0.0001784752],"domain_scores_gemma":[0.9755659,0.01965893,0.003808167,0.0002484622,0.000509685,0.0002089026],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9237702,0.003580077,0.00571015,0.00005044684,0.00844685,0.00008634174,0.002193057,0.000009949778,0.00022395,0.00001332522,0.0003797353,0.05553589],"study_design_scores_gemma":[0.8721866,0.111239,0.002654957,0.0000772653,0.005387204,0.00003502244,0.0001372981,0.001303155,0.001118427,0.00003467924,0.005762626,0.00006373445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737605,0.003812852,0.0004261052,0.01740051,0.0008861148,0.003562263,0.00006369584,0.000003558082,0.00008437788],"genre_scores_gemma":[0.9933854,0.003294953,0.001298754,0.0009944745,0.0008413334,0.00006036021,0.000006829835,0.00001702515,0.0001009207],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1076589,"threshold_uncertainty_score":0.3942258,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2171015116","doi":"10.1200/jco.2009.24.9284","title":"Breast Cancer Subtypes and the Risk of Local and Regional Relapse","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1242,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Breast cancer; Medicine; Progesterone receptor; Cytokeratin; Oncology; Internal medicine; Tissue microarray; Immunohistochemistry; Estrogen receptor; Cancer; Epidermal growth factor receptor; Proportional hazards model; Lymph node; Basal (medicine); Mastectomy; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02651815263737387,"gpt":0.3787242963253215,"spread":0.3522061436879476,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001262993,0.00007893658,0.0004632554,0.00001645689,0.00004528732,0.000003173723,0.00009487927,0.0002105842,0.00001319306],"category_scores_gemma":[0.0003895412,0.00004204957,0.0001459,0.00002558877,0.00142069,0.000003748851,0.00008294502,0.0003968275,3.430741e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000006373131,"about_ca_system_score_gemma":0.0002909973,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000148271,"about_ca_topic_score_gemma":0.0006803799,"domain_scores_codex":[0.9988737,0.0002222443,0.0005990991,0.0001205217,0.00009565124,0.00008885783],"domain_scores_gemma":[0.9981666,0.0006156912,0.0008081039,0.0001101679,0.0002125925,0.00008691063],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01367002,0.0004271882,0.6851854,0.00001479964,0.001431358,0.00001833127,0.0001273376,0.00001323791,0.001297948,0.000994703,0.005804163,0.2910155],"study_design_scores_gemma":[0.007144263,0.000810461,0.9655209,0.00001414989,0.0003467533,0.0007786158,0.0001344252,0.00001385191,0.0002779439,0.0008169772,0.02407872,0.00006296283],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869154,0.002994855,0.00008148052,0.009304854,0.0004625159,0.00004528364,0.00001709068,8.202284e-7,0.0001776807],"genre_scores_gemma":[0.9875147,0.01086749,0.0004334398,0.0004717145,0.0006672092,0.000002719591,6.983487e-7,0.00000573436,0.00003624029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2909526,"threshold_uncertainty_score":0.5234591,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106869018","doi":"10.1200/jco.2014.55.1192","title":"Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1220,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Prostate cancer; Watchful waiting; Cancer; Cohort; Hazard ratio; Prostate; Internal medicine; Prostate-specific antigen; Prospective cohort study; Oncology; Cohort study; Gynecology; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.03777705958447385,"gpt":0.4154668623716197,"spread":0.3776898027871458,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001296475,0.0001287488,0.0016805,0.00006576098,0.00001695506,0.000001986728,0.00009434321,0.0001502546,0.00009770675],"category_scores_gemma":[0.0008094562,0.0000764696,0.000288615,0.0001081346,0.0001773334,0.00007090628,0.00003313005,0.0003374913,0.000001499593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001562226,"about_ca_system_score_gemma":0.0009611082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003312229,"about_ca_topic_score_gemma":0.0002538129,"domain_scores_codex":[0.9974545,0.0002435411,0.0015399,0.0001684874,0.0003887363,0.0002048292],"domain_scores_gemma":[0.994825,0.0009572741,0.002628223,0.0001815731,0.001183926,0.000223996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01545527,0.002789658,0.9091917,0.00008484205,0.001046666,0.00003948723,0.0001062274,0.000004154483,0.00001012064,0.00001467776,0.0004293875,0.07082779],"study_design_scores_gemma":[0.02438234,0.02123527,0.9503719,0.0003006886,0.0004399185,0.00000645311,0.00001322058,0.000005051994,0.0004417986,0.0000238724,0.002713857,0.00006567385],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970842,0.0003232525,0.00003686072,0.0009747082,0.0006978472,0.0004242101,0.00007737482,0.000002972789,0.0003786028],"genre_scores_gemma":[0.9974155,0.001594942,0.0002268259,0.000428569,0.0002045382,0.00001728331,0.00001283548,0.00001529205,0.00008422301],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07076211,"threshold_uncertainty_score":0.311834,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2947775394","doi":"10.1200/jco.19.00934","title":"Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1185,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Pembrolizumab; Overall survival; Lung cancer; Safety profile; Phases of clinical research; Survival rate; Cancer; Lung","retraction":null,"screen_n_in":null,"score":{"opus":0.04314214802703654,"gpt":0.41046673368768,"spread":0.3673245856606435,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001303204,0.0002287676,0.001318609,0.00005239204,0.00006518605,0.00001643309,0.0002498374,0.0002137691,0.0001462808],"category_scores_gemma":[0.0003299956,0.0001095347,0.0002923182,0.000132795,0.0001184828,0.0001064767,0.00002880304,0.0006702083,0.000003986321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002160834,"about_ca_system_score_gemma":0.001227233,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005998812,"about_ca_topic_score_gemma":0.0006740182,"domain_scores_codex":[0.9970221,0.0003070209,0.001606067,0.0003336384,0.0004377814,0.0002933878],"domain_scores_gemma":[0.9940013,0.002860307,0.001861461,0.0003607323,0.0007187934,0.0001973758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5069,0.008801681,0.4618699,0.00001808505,0.001502027,0.00006349218,0.0003464732,0.00005990962,0.0001294848,5.651299e-7,0.002462503,0.01784584],"study_design_scores_gemma":[0.3197525,0.08178364,0.583197,0.0001826613,0.000922045,0.00000507761,0.0003736066,0.0001238783,0.00004051127,0.000002835066,0.0134721,0.0001441624],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949187,0.0002102493,0.00002952657,0.00130581,0.0009149317,0.001851518,0.0001532204,0.000009561762,0.000606453],"genre_scores_gemma":[0.9962134,0.0003029879,0.0005825346,0.001175649,0.0006551133,0.00002475715,0.00004631916,0.00003721593,0.0009619929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1871476,"threshold_uncertainty_score":0.4466696,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149568734","doi":"10.1200/jco.2006.08.2024","title":"Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1172,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Alberta; University of Ottawa; University of British Columbia","funders":"","keywords":"Medicine; Aerobic exercise; Breast cancer; Quality of life (healthcare); Physical therapy; Randomized controlled trial; Internal medicine; Psychosocial; Lymphedema; Cancer; Lean body mass; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.01823382411926726,"gpt":0.3822727521623391,"spread":0.3640389280430718,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007334075,0.0001401349,0.004325919,0.000161915,0.0000139458,0.000004212659,0.00008235563,0.0002843093,0.00004342126],"category_scores_gemma":[0.003380495,0.00008836998,0.0006807531,0.0001228061,0.0002105331,0.00006287647,0.00001996597,0.0005722597,3.935911e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000140534,"about_ca_system_score_gemma":0.0004691013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001026286,"about_ca_topic_score_gemma":0.0009856554,"domain_scores_codex":[0.9955418,0.0006756459,0.003074129,0.0001611153,0.0003351239,0.0002121816],"domain_scores_gemma":[0.9892471,0.007722902,0.002243543,0.00009508434,0.0004662916,0.0002250937],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9227537,0.001800688,0.03174679,0.0001585471,0.0002784529,0.00008707842,0.0004632605,3.207009e-7,0.0001114156,0.000003637837,0.0001686223,0.04242751],"study_design_scores_gemma":[0.7833545,0.001230844,0.2130857,0.001269826,0.0005371044,0.000004961703,0.00005043536,0.000009109059,0.00006536905,0.00002991008,0.0003020074,0.00006027563],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990117,0.003603119,0.00003812437,0.001486701,0.002482276,0.001949802,0.000001311484,0.000003453408,0.000318264],"genre_scores_gemma":[0.992135,0.006113519,0.0002734772,0.0007748717,0.0005192831,0.00003416701,4.204988e-7,0.00001466091,0.0001345774],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1813389,"threshold_uncertainty_score":0.4047012,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2147013683","doi":"10.1200/jco.2012.43.2674","title":"Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":1163,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; McGill University","funders":"National Cancer Institute","keywords":"Medicine; Procarbazine; Lomustine; Internal medicine; Hazard ratio; Oligodendroglial Tumor; Vincristine; Oligodendroglioma; Gastroenterology; Chemoradiotherapy; Radiation therapy; Proportional hazards model; Nuclear medicine; Oncology; Chemotherapy; Glioma; Confidence interval; Astrocytoma","retraction":null,"screen_n_in":null,"score":{"opus":0.146231725299461,"gpt":0.5003239368345028,"spread":0.3540922115350418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002829778,0.0001528492,0.002435895,0.0002061708,0.00002046768,0.000002764396,0.0001367018,0.0003464001,0.00006646437],"category_scores_gemma":[0.003322693,0.0001018997,0.0009519187,0.0001502863,0.0002037941,0.00009353562,0.00001998429,0.0002867195,0.000002342419],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009394892,"about_ca_system_score_gemma":0.0005867457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006332171,"about_ca_topic_score_gemma":0.000008947304,"domain_scores_codex":[0.9955682,0.0001853849,0.003482526,0.0001426054,0.0003431147,0.00027821],"domain_scores_gemma":[0.9912486,0.004271647,0.003341547,0.0002378221,0.0004717141,0.0004286501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.718096,0.07268079,0.02216803,0.0001325436,0.002218752,0.0003369149,0.0002097996,0.000004659501,0.003558793,0.0001551041,0.005648852,0.1747898],"study_design_scores_gemma":[0.8123072,0.1277304,0.03623569,0.0001822076,0.001632563,0.0003124365,0.00002739989,0.0000395295,0.0157536,0.00004901924,0.005629741,0.0001001802],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938782,0.001115123,0.0002190716,0.001617159,0.002188892,0.0005908707,0.00002948301,0.000004137467,0.0003570236],"genre_scores_gemma":[0.9941249,0.0005831475,0.002453271,0.0002021808,0.002555042,0.00001297549,0.000008627022,0.00001844637,0.00004134852],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1746896,"threshold_uncertainty_score":0.4155349,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009099064","doi":"10.1200/jco.19.03136","title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1154,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Internal medicine; Hazard ratio; Placebo; Oncology; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Surgery; Cancer; Progressive disease; Chemotherapy; Confidence interval; Pathology; Immunotherapy; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.1020767828221736,"gpt":0.432874076965801,"spread":0.3307972941436275,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001486139,0.000292756,0.002894302,0.0002370935,0.00007703072,0.00003009373,0.0002241437,0.0003624385,0.001233588],"category_scores_gemma":[0.001549557,0.0001932932,0.0009759857,0.0007523168,0.0001774403,0.00009568721,0.00005525518,0.0007262219,0.000003560664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002986494,"about_ca_system_score_gemma":0.002985124,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007594969,"about_ca_topic_score_gemma":0.001146735,"domain_scores_codex":[0.9956742,0.0004178964,0.002791268,0.0004176742,0.0003252881,0.0003736897],"domain_scores_gemma":[0.9930788,0.003371416,0.002235746,0.000216568,0.0004679413,0.0006295579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7553523,0.001739426,0.053486,0.0004940199,0.03524272,0.001624012,0.00251663,0.000986931,0.004237911,0.00000246827,0.03290837,0.1114092],"study_design_scores_gemma":[0.4306829,0.067333,0.1165393,0.0005425394,0.1105657,0.0003580475,0.002472692,0.1896623,0.002567722,0.00005325656,0.07796703,0.001255462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816464,0.003319299,0.004234041,0.00881709,0.0004707316,0.001137499,0.0001293222,0.00002373774,0.0002219047],"genre_scores_gemma":[0.9803936,0.002354047,0.008489456,0.007211031,0.000796539,0.0000388597,0.00007362713,0.00004445355,0.0005983497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3246694,"threshold_uncertainty_score":0.9996794,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2147058464","doi":"10.1200/jco.2004.04.188","title":"Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: The PROSE Study Group","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"BRCA gene mutations in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1146,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Prophylactic Mastectomy; Breast cancer; Prophylactic Surgery; Mastectomy; Oophorectomy; Cancer; BRCA mutation; Gynecology; Surgery; Germline mutation; Ovarian cancer; Oncology; Internal medicine; Hysterectomy; Mutation","retraction":null,"screen_n_in":null,"score":{"opus":0.03248792481459869,"gpt":0.3905868678752462,"spread":0.3580989430606475,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002392613,0.0001529424,0.0004716577,0.0000709337,0.0000880026,0.00003183721,0.0002456119,0.0002557367,0.00001002308],"category_scores_gemma":[0.0006262752,0.00009772433,0.0001375592,0.0001814708,0.0003216541,0.00002432379,0.00008834069,0.0006711644,0.000001400411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001901637,"about_ca_system_score_gemma":0.001380211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001683958,"about_ca_topic_score_gemma":0.0009877654,"domain_scores_codex":[0.9973575,0.0006536652,0.001253076,0.0003024815,0.0002230917,0.000210132],"domain_scores_gemma":[0.9980645,0.00017129,0.001170984,0.0002062695,0.0002646849,0.0001222304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01004789,0.005429784,0.5439049,0.00006330664,0.001477795,0.0004760512,0.005088087,0.01145088,0.02591674,0.00004147607,0.0009221074,0.395181],"study_design_scores_gemma":[0.01734451,0.01339309,0.9529557,0.00006000097,0.0004113467,0.001087006,0.003068491,0.00003492547,0.003588128,0.001128815,0.006600168,0.0003278782],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937656,0.001265644,0.00006924338,0.003381846,0.000957433,0.0004604259,0.00001408117,0.000003326807,0.00008242478],"genre_scores_gemma":[0.9968079,0.0006241731,0.0007331618,0.0006132515,0.001120312,0.00004995266,0.000002135849,0.00001934173,0.00002980539],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4090507,"threshold_uncertainty_score":0.3985082,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165542862","doi":"10.1200/jco.2007.12.4008","title":"Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1145,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Docetaxel; Mitoxantrone; Prednisone; Prostate cancer; Internal medicine; Urology; Survival analysis; Surgery; Oncology; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.2067678927162186,"gpt":0.5167604900016837,"spread":0.309992597285465,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004571894,0.0002888795,0.002362962,0.0002004199,0.0001818048,0.00001843408,0.0004612457,0.0003201059,0.0001274701],"category_scores_gemma":[0.002215875,0.0001477644,0.0004292662,0.0004862683,0.0004479719,0.00021415,0.00009236702,0.001409863,0.000008555526],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007896245,"about_ca_system_score_gemma":0.007858319,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001727697,"about_ca_topic_score_gemma":0.001064004,"domain_scores_codex":[0.9942851,0.00099088,0.002722342,0.0004144565,0.0008996059,0.0006875964],"domain_scores_gemma":[0.9942452,0.002771704,0.001420877,0.0003801434,0.0007916718,0.0003903717],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4987577,0.02397811,0.2909245,0.0002699508,0.003449678,0.01324713,0.009835739,0.0009790984,0.0006565691,0.00003900536,0.04414036,0.1137222],"study_design_scores_gemma":[0.2911211,0.1226603,0.4361692,0.0003454549,0.00137869,0.001181977,0.008484102,0.001127798,0.000307253,0.0001977771,0.136551,0.0004754077],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.974713,0.002708249,0.00006985968,0.0170017,0.001462082,0.003599242,0.00006639762,0.0000181533,0.000361289],"genre_scores_gemma":[0.9814227,0.008455556,0.001385774,0.0007712009,0.001422002,0.0003069889,0.00002322704,0.0000428373,0.006169746],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2076366,"threshold_uncertainty_score":0.9977662,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2141604895","doi":"10.1200/jco.2014.57.2909","title":"Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":1137,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Hippocampal formation; Compartment (ship); Whole brain radiotherapy; Radiation therapy; Neural stem cell; Internal medicine; Stem cell; Brain metastasis; Cancer; Metastasis; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1231112028158909,"gpt":0.4379247600735918,"spread":0.3148135572577009,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004453467,0.0002068579,0.001664976,0.00009188306,0.0001315148,0.000006492632,0.0002138586,0.0001483024,0.00003683979],"category_scores_gemma":[0.001091238,0.0001084049,0.000749111,0.0001144686,0.0004784774,0.0001825258,0.00004503987,0.0004274791,3.868195e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001124549,"about_ca_system_score_gemma":0.001079463,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001334243,"about_ca_topic_score_gemma":0.00002934994,"domain_scores_codex":[0.9957158,0.0009420718,0.002395016,0.0001917408,0.0005175458,0.0002378503],"domain_scores_gemma":[0.9928264,0.003317172,0.002937628,0.0002785356,0.0004274133,0.000212845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7416958,0.05104147,0.007177013,0.0008360696,0.004666017,0.0001437428,0.00114117,0.01051516,0.01662006,0.00158082,0.007299225,0.1572835],"study_design_scores_gemma":[0.7504274,0.1465507,0.01825538,0.0003024833,0.00142888,0.0003277395,0.0002628879,0.01053824,0.009872632,0.00006550801,0.06175212,0.0002160925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768874,0.0003547644,0.008110475,0.01241523,0.0007132224,0.001378106,0.00009141537,0.000005506979,0.00004385052],"genre_scores_gemma":[0.9844293,0.0000186342,0.0129723,0.001493986,0.0006965401,0.00003251725,0.00001889658,0.00001566548,0.0003221372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1570674,"threshold_uncertainty_score":0.4420624,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3154805493","doi":"10.1200/jco.21.00174","title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1109,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Chemotherapy; Lung cancer; Hazard ratio; Oncology; Clinical endpoint; Cancer; Surgery; Randomized controlled trial; Immunotherapy; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.08258638092140791,"gpt":0.4375760962292222,"spread":0.3549897153078143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154555,0.0002110467,0.001496945,0.0000862329,0.0000600933,0.00001798482,0.0001294422,0.0001491685,0.0003545884],"category_scores_gemma":[0.0003125173,0.0001213475,0.0005190231,0.0001829194,0.000200943,0.00009930445,0.00001545709,0.000566242,0.000001850256],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002846403,"about_ca_system_score_gemma":0.005502399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005049262,"about_ca_topic_score_gemma":0.0003529413,"domain_scores_codex":[0.9974313,0.0001416858,0.001467507,0.0002694699,0.0003938848,0.0002961789],"domain_scores_gemma":[0.9961308,0.0008953079,0.001696175,0.0002236898,0.0008205129,0.0002335382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6125771,0.004374218,0.2976188,0.0007353609,0.007841227,0.00205811,0.0004755285,0.00008759458,0.00216627,0.00003174751,0.007818514,0.06421545],"study_design_scores_gemma":[0.278909,0.06574297,0.5732024,0.0009054187,0.004845566,0.001045664,0.001434765,0.00035287,0.003987995,0.00004282724,0.06903633,0.0004942667],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856274,0.00132414,0.001045129,0.009631712,0.001020289,0.000681775,0.00001087101,0.00001116142,0.0006474874],"genre_scores_gemma":[0.9612191,0.002013221,0.02547897,0.007031133,0.001067011,0.00007821779,0.00001383413,0.00007940272,0.003019142],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3336682,"threshold_uncertainty_score":0.9761019,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3217126890","doi":"10.1200/jco.21.02229","title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1104,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Alberta Cancer Foundation","funders":"National Cancer Institute; EMD Serono; Genentech; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Amgen; Celldex Therapeutics; Array BioPharma; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Melanoma; Metastatic melanoma; Clinical trial; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.07445865462662754,"gpt":0.4172274161971886,"spread":0.342768761570561,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001055658,0.0003277401,0.002506908,0.0002027681,0.00006481287,0.00002149181,0.0002585247,0.00043083,0.0005245098],"category_scores_gemma":[0.001077225,0.0001935427,0.0004635754,0.0004831111,0.0003786954,0.0002733536,0.00007042516,0.00118742,0.00001267167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008962182,"about_ca_system_score_gemma":0.005240915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003377469,"about_ca_topic_score_gemma":0.002304273,"domain_scores_codex":[0.9954136,0.0003884142,0.002490149,0.000433071,0.0007879325,0.0004868311],"domain_scores_gemma":[0.9949703,0.001658206,0.00169434,0.0004778527,0.0008274578,0.0003718711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3480144,0.00274259,0.5247004,0.00004475356,0.001160145,0.003079387,0.00009290258,0.0000122984,0.00002261021,0.000003168288,0.0002534264,0.1198738],"study_design_scores_gemma":[0.205177,0.05007746,0.7399107,0.0003620593,0.0004049891,0.0003112063,0.0001778579,0.000007200481,0.00007107936,0.000004206734,0.003285249,0.0002110323],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9935613,0.0007283572,0.00005375833,0.00259199,0.001717326,0.0004093765,0.000007883538,0.00001859749,0.000911462],"genre_scores_gemma":[0.9933701,0.0006660518,0.002983546,0.0014752,0.0003203605,0.000009570471,0.00001932564,0.0000512925,0.001104556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2152102,"threshold_uncertainty_score":0.9297158,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2129931005","doi":"10.1200/jco.2007.13.4452","title":"Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1077,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Imatinib mesylate; Imatinib; GiST; Regimen; Internal medicine; Surgery; Oncology; Phases of clinical research; Clinical trial; Gastroenterology; Tyrosine-kinase inhibitor; Progression-free survival; Chemotherapy; Stromal cell; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1692056531082675,"gpt":0.4733452979920085,"spread":0.304139644883741,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007107732,0.000407438,0.003439924,0.0002902778,0.0002380097,0.00006532886,0.0003584058,0.00006944214,0.0005842464],"category_scores_gemma":[0.01667129,0.0001944073,0.0006333539,0.0003793101,0.00108836,0.0004234565,0.0001916266,0.001818015,0.00001648048],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005972161,"about_ca_system_score_gemma":0.002698068,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007514468,"about_ca_topic_score_gemma":0.00004691688,"domain_scores_codex":[0.9908093,0.002680416,0.00405273,0.0004105014,0.001249661,0.0007974575],"domain_scores_gemma":[0.9865208,0.008448825,0.003124616,0.0003424416,0.0007928656,0.0007704012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9376905,0.01115905,0.03373248,0.00003843485,0.0003691444,0.009041002,0.0001100605,0.0000451856,0.0003888537,0.000009832721,0.0006098198,0.006805665],"study_design_scores_gemma":[0.8753955,0.08784369,0.02832358,0.001531008,0.0004689417,0.005210544,0.0001632719,0.000546645,0.0001684612,0.0000374449,0.0001534578,0.0001574058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947917,0.000121659,0.001120298,0.00161642,0.0003168733,0.00172334,0.00001465663,0.00001660752,0.0002784888],"genre_scores_gemma":[0.951799,0.00002061041,0.04692358,0.0002736296,0.0005245562,0.00004933102,0.00001941622,0.00004469743,0.0003451991],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07668464,"threshold_uncertainty_score":0.9916117,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157996158","doi":"10.1200/jco.2009.24.2180","title":"Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Diagnosis and Treatment","field":"Medicine","cited_by":1069,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Watchful waiting; Prostate cancer; Hazard ratio; Cohort; Cancer; Prostate-specific antigen; Internal medicine; Prostate; Prospective cohort study; Proportional hazards model; Cohort study; Oncology; Gynecology; Surgery; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.06908816564333845,"gpt":0.4725403227283844,"spread":0.403452157085046,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00426434,0.0002128622,0.003208644,0.00009918342,0.00002477092,0.00000397466,0.0001704157,0.0003577908,0.00006094434],"category_scores_gemma":[0.002276693,0.0001292762,0.0007107067,0.0002309359,0.0003876704,0.00009716644,0.00003506448,0.0008028938,0.000002148618],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002011771,"about_ca_system_score_gemma":0.002859032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005144843,"about_ca_topic_score_gemma":0.0003604658,"domain_scores_codex":[0.9939204,0.0005793828,0.004277965,0.0003390645,0.0005538839,0.0003293146],"domain_scores_gemma":[0.9906977,0.002306567,0.004796693,0.000337865,0.001424915,0.0004361918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07416782,0.004370728,0.7364061,0.00004642833,0.001398232,0.0007094818,0.0001004533,0.00001030745,0.00001994679,0.00001418972,0.001933909,0.1808223],"study_design_scores_gemma":[0.0560682,0.04787855,0.8880019,0.0006326925,0.0007527356,0.00008831901,0.00003397809,0.00001235818,0.0006497629,0.00005230285,0.005722682,0.000106557],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989824,0.001345705,0.00005999368,0.006148477,0.000911842,0.0006562729,0.0001257965,0.000007708967,0.0009202019],"genre_scores_gemma":[0.9826416,0.01435237,0.0009775371,0.001260426,0.0004800718,0.00001276371,0.00001645157,0.0000172694,0.0002414705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1807158,"threshold_uncertainty_score":0.5271729,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137383164","doi":"10.1200/jco.2007.14.6217","title":"Cancer Survivors’ Adherence to Lifestyle Behavior Recommendations and Associations With Health-Related Quality of Life: Results From the American Cancer Society's SCS-II","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":1025,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Dalhousie University","funders":"","keywords":"Medicine; Psychological intervention; Quality of life (healthcare); Cancer; Gerontology; Cancer survivor; Demography; Internal medicine; Psychiatry","retraction":null,"screen_n_in":null,"score":{"opus":0.24266289197625,"gpt":0.5096895033310943,"spread":0.2670266113548443,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003212649,0.0001300849,0.001517764,0.00003818152,0.0003061884,0.000004847263,0.0001617858,0.0001605778,0.0000961685],"category_scores_gemma":[0.002717853,0.00008252601,0.0002980552,0.0004338557,0.0004465082,0.00007221673,0.00008151335,0.0009121643,0.000001131408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000278804,"about_ca_system_score_gemma":0.004824925,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.1638292,"about_ca_topic_score_gemma":0.2206943,"domain_scores_codex":[0.9956098,0.000885278,0.002633577,0.0002307891,0.000421507,0.0002190859],"domain_scores_gemma":[0.989977,0.004317157,0.00414025,0.0002321491,0.0008472945,0.00048616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001911154,0.0006713128,0.923956,0.000008681105,0.0004853616,0.000009090442,0.008307294,0.00001403254,0.00002222871,0.000007882909,0.02028946,0.04431755],"study_design_scores_gemma":[0.00368194,0.005685686,0.9704759,0.0001484842,0.0002442318,0.00001295321,0.001908797,0.000007969063,0.000006135213,0.00001212745,0.01772531,0.00009047733],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8951995,0.001286388,0.00002978363,0.1017907,0.0008640035,0.0002502151,0.0004852839,0.000008935639,0.00008518597],"genre_scores_gemma":[0.9802786,0.007801021,0.001065765,0.009902772,0.0006264985,0.00003036038,0.0000216734,0.00001477535,0.0002586029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09188795,"threshold_uncertainty_score":0.855921,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125885282","doi":"10.1200/jco.2014.58.1967","title":"Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1023,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Medicine; Carboplatin; Chemotherapy; Oncology; Human Epidermal Growth Factor Receptor 2; Triple-negative breast cancer; Internal medicine; Triple negative; Breast cancer; Cancer research; Epidermal growth factor receptor; Receptor; Pathology; Cancer; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.03804349880468626,"gpt":0.3858530708677692,"spread":0.3478095720630829,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00310928,0.0002198564,0.001578435,0.0001887143,0.00007208447,0.00001958715,0.00008915266,0.0001919636,0.00007982353],"category_scores_gemma":[0.001592087,0.0001363888,0.0001213331,0.0002020757,0.0004097018,0.0001417498,0.00002665201,0.0005538995,4.977374e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006870827,"about_ca_system_score_gemma":0.002199847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000512038,"about_ca_topic_score_gemma":0.0005512962,"domain_scores_codex":[0.9967146,0.0009280184,0.001529736,0.0002864085,0.0002701657,0.0002711051],"domain_scores_gemma":[0.9943917,0.003742065,0.001131845,0.0001141852,0.0002523782,0.000367848],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.49122,0.0003557883,0.2150425,0.00006094875,0.0004959861,0.0002568779,0.003136872,0.00000294172,0.0457468,0.000008006648,0.0002733458,0.2433999],"study_design_scores_gemma":[0.03981677,0.02889312,0.9237468,0.000577693,0.0000833264,0.001598679,0.0007623758,0.00007340961,0.00305927,0.00001700168,0.001169731,0.0002018056],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929476,0.0001716644,0.0000565651,0.005848472,0.0001869841,0.0004361584,0.00001453884,0.000008487396,0.0003295739],"genre_scores_gemma":[0.986546,0.000230565,0.005833364,0.006814192,0.0004315174,0.000008821954,0.000001362264,0.00002678534,0.000107406],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7087044,"threshold_uncertainty_score":0.5561773,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130244150","doi":"10.1200/jco.2005.08.391","title":"Dignity Therapy: A Novel Psychotherapeutic Intervention for Patients Near the End of Life","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Patient Dignity and Privacy","field":"Medicine","cited_by":1020,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Manitoba; CancerCare Manitoba; St. Boniface Hospital","funders":"","keywords":"Dignity; Medicine; Intervention (counseling); Psychosocial; Feeling; Distress; Palliative care; Meaning (existential); Psychotherapist; Depression (economics); Psychiatry; Nursing; Clinical psychology; Psychology; Social psychology","retraction":null,"screen_n_in":null,"score":{"opus":0.3032002047393502,"gpt":0.5107964315329052,"spread":0.207596226793555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002501683,0.0000846,0.0007254345,0.00004767693,0.00005457796,0.000007910858,0.0001884485,0.0002011667,0.0001397222],"category_scores_gemma":[0.002906381,0.00004801344,0.0006932884,0.00007606104,0.0002879489,0.0001006307,0.00001787023,0.0004797601,0.000006032033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003910031,"about_ca_system_score_gemma":0.0005788638,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006164933,"about_ca_topic_score_gemma":0.00001125283,"domain_scores_codex":[0.9974587,0.0002518232,0.001820403,0.00009163435,0.0002455814,0.0001318601],"domain_scores_gemma":[0.9951832,0.002231825,0.0017722,0.0001631173,0.0004914459,0.000158243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01601117,0.01338817,0.09516155,0.00003919383,0.0006405542,0.00000117216,0.0006249925,0.000007996568,0.0001422094,0.0001260503,0.002313917,0.871543],"study_design_scores_gemma":[0.03095348,0.03106939,0.4668445,0.0001030678,0.0002282542,0.00001175367,0.0000650449,0.000260961,0.00009810448,0.0009749893,0.469321,0.00006939619],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871226,0.0003863353,0.001652504,0.009026664,0.0007739645,0.0003727461,0.000008405326,0.000003813618,0.0006529501],"genre_scores_gemma":[0.9895477,0.0003172412,0.003402766,0.005911405,0.0007401493,0.000004377492,0.00000303187,0.000009994083,0.00006328727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8714736,"threshold_uncertainty_score":0.3479419,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2121708973","doi":"10.1200/jco.2004.09.059","title":"Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":1015,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Stage (stratigraphy); Adjuvant therapy; Internal medicine; Proportional hazards model; Colorectal cancer; Levamisole; Multivariate analysis; Oncology; Adjuvant; Survival analysis; Cancer; Radiation therapy; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.09422666171105251,"gpt":0.4446239429035839,"spread":0.3503972811925314,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001285508,0.0001774368,0.002515818,0.0002054467,0.00006608431,0.000008832139,0.00009032917,0.000323195,0.00007404591],"category_scores_gemma":[0.000763545,0.0001210959,0.0005514693,0.0003149259,0.0002402895,0.00008001426,0.0000363855,0.0003555926,1.092927e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002379243,"about_ca_system_score_gemma":0.0009418098,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001440829,"about_ca_topic_score_gemma":0.0004185015,"domain_scores_codex":[0.9977448,0.000151528,0.001297577,0.0002603044,0.000317961,0.0002278519],"domain_scores_gemma":[0.9956393,0.001842339,0.001476907,0.0001418495,0.0004929205,0.0004067124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05370839,0.004219028,0.211366,0.00007960123,0.01151026,0.0002109623,0.0003136184,0.0004399592,0.002270369,0.0001305217,0.001107149,0.7146442],"study_design_scores_gemma":[0.1207907,0.1166994,0.6901672,0.0003439517,0.01281451,0.00005367297,0.0002131395,0.001429077,0.005997797,0.0002236535,0.05092428,0.0003427139],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733699,0.01047064,0.0001097176,0.01519754,0.0002132143,0.0004397962,0.0001186894,0.00000640936,0.00007410366],"genre_scores_gemma":[0.9874581,0.009480352,0.001119056,0.001560015,0.0001563128,0.00002321853,0.00001094468,0.00001488913,0.0001771399],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7143015,"threshold_uncertainty_score":0.4938146,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2983284890","doi":"10.1200/jco.19.02107","title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1014,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Pembrolizumab; Cohort; Colorectal cancer; Tolerability; Oncology; Microsatellite instability; Irinotecan; Progression-free survival; Clinical endpoint; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Phases of clinical research; Adverse effect; Chemotherapy; Clinical trial; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1353295079761783,"gpt":0.4909100416450203,"spread":0.355580533668842,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003820299,0.0002767458,0.0029882,0.0002514583,0.00005677871,0.00001508449,0.0003741621,0.0002678471,0.0004275306],"category_scores_gemma":[0.000507247,0.0001894996,0.0004894733,0.000409887,0.0002532552,0.0001882548,0.0001388788,0.0007231069,0.000008112178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009700495,"about_ca_system_score_gemma":0.003173533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001976298,"about_ca_topic_score_gemma":0.001504325,"domain_scores_codex":[0.9936345,0.0009558199,0.004162657,0.0004242735,0.0004630263,0.0003597058],"domain_scores_gemma":[0.9949256,0.001398471,0.002591553,0.0004199415,0.0004095693,0.0002549161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3082857,0.2755408,0.1097114,0.0001365581,0.003245211,0.0007598472,0.003551851,0.0000302927,0.03006727,0.00001605949,0.0003678603,0.2682871],"study_design_scores_gemma":[0.391169,0.4691904,0.0983146,0.0003664415,0.001143039,0.0002591222,0.002370868,0.0001820757,0.00162534,0.00004792332,0.03506525,0.0002659979],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931742,0.001987815,0.000002274912,0.001051897,0.001609577,0.001769879,0.00003002584,0.00001132288,0.0003630102],"genre_scores_gemma":[0.996576,0.001752985,0.0006027542,0.0005501934,0.000150366,0.00003017022,0.000007178211,0.00002781316,0.0003025786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2680211,"threshold_uncertainty_score":0.7727568,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2904444972","doi":"10.1200/jco.2018.78.2276","title":"T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":992,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Clinical endpoint; Cancer; Response Evaluation Criteria in Solid Tumors; Lung cancer; KRAS; Clinical trial; Phases of clinical research; Immunotherapy; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0401353546324534,"gpt":0.3951411541431732,"spread":0.3550057995107199,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001294054,0.0002435736,0.001121799,0.0001311637,0.0001068163,0.00002710463,0.0001701554,0.0003546576,0.00008125183],"category_scores_gemma":[0.0007238489,0.0001500387,0.0001960739,0.0002254327,0.0005888455,0.0001763968,0.00005785758,0.0006798065,0.000003524588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003071624,"about_ca_system_score_gemma":0.001788741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009138678,"about_ca_topic_score_gemma":0.00005841186,"domain_scores_codex":[0.9963918,0.00031262,0.001944642,0.0003618621,0.0005744076,0.000414657],"domain_scores_gemma":[0.9963824,0.0006542663,0.001639057,0.0002048858,0.0007176774,0.0004017171],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1924358,0.002787822,0.7453531,0.00007256705,0.0002944248,0.0004915149,0.001026454,0.00001635311,0.01375907,4.172196e-7,0.002732519,0.04102992],"study_design_scores_gemma":[0.08046674,0.03153595,0.8630435,0.000763825,0.0001553899,0.0002134701,0.0001604601,0.0001151855,0.01762388,0.00000820556,0.005725017,0.0001883279],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974234,0.0003747967,0.00002035069,0.0006126511,0.000368212,0.0008077048,0.00002037749,0.00001770096,0.000354884],"genre_scores_gemma":[0.9952334,0.0001824146,0.002682353,0.0004665231,0.001140927,0.0000315965,0.00002880925,0.00003131642,0.0002027237],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1176904,"threshold_uncertainty_score":0.6118401,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139891818","doi":"10.1200/jco.2011.38.0402","title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":990,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Seagen (Canada)","funders":"Takeda Oncology","keywords":"Brentuximab vedotin; Medicine; Anaplastic large-cell lymphoma; Internal medicine; Neutropenia; Antibody-drug conjugate; Phases of clinical research; Refractory (planetary science); Oncology; CD30; Adverse effect; Lymphoma; Gastroenterology; Chemotherapy; Immunology; Antibody; Monoclonal antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.05924066866749524,"gpt":0.4100624161401102,"spread":0.350821747472615,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00319185,0.0002270051,0.002129924,0.0002478317,0.00004543801,0.000004300372,0.0001545336,0.0003048943,0.00004138225],"category_scores_gemma":[0.002811887,0.0001268417,0.0002705371,0.0002617084,0.00009434174,0.0001691343,0.00007828018,0.0003895775,0.00001393253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000583372,"about_ca_system_score_gemma":0.001583723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003538698,"about_ca_topic_score_gemma":0.00008038376,"domain_scores_codex":[0.9943848,0.0007306376,0.003597907,0.0002449625,0.0006275878,0.0004141675],"domain_scores_gemma":[0.9929075,0.002702887,0.003145382,0.0003277029,0.0004262275,0.0004902562],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08750263,0.269597,0.6161203,0.00005500649,0.0004323373,0.0006992387,0.0006238963,0.000002412259,0.000007249552,0.000002669077,0.001331133,0.02362612],"study_design_scores_gemma":[0.2913716,0.1708482,0.5330142,0.000354415,0.0007104037,0.00008739443,0.0004292887,0.0000112691,0.00001855691,9.616061e-7,0.00306997,0.00008373948],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971379,0.0005109746,0.000004516281,0.0001884553,0.00100257,0.0006911681,0.00002715024,0.000007393602,0.0004298814],"genre_scores_gemma":[0.9987565,0.0001331538,0.0003499395,0.0002062886,0.0003666779,0.00001301524,0.00000985361,0.00002372428,0.000140879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2038689,"threshold_uncertainty_score":0.5172456,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2145304413","doi":"10.1200/jco.2005.09.137","title":"Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":989,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; International Prognostic Index; Internal medicine; Vincristine; Diffuse large B-cell lymphoma; Prednisone; CHOP; Population; Cyclophosphamide; Lymphoma; Gastroenterology; Oncology; Surgery; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.04227816456457361,"gpt":0.3824355696899724,"spread":0.3401574051253988,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00222366,0.0001231208,0.002393829,0.00009560715,0.00002374093,0.00001708856,0.0001604817,0.0003865047,0.0003098228],"category_scores_gemma":[0.001804552,0.000122907,0.0005880951,0.0001661503,0.0001893935,0.000115874,0.00004495206,0.0003204963,0.000008702478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004299795,"about_ca_system_score_gemma":0.000912395,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009784792,"about_ca_topic_score_gemma":0.004751514,"domain_scores_codex":[0.9949046,0.000324567,0.00394853,0.0002094849,0.0003516822,0.0002610799],"domain_scores_gemma":[0.9957454,0.001114088,0.002159519,0.0002600173,0.000476225,0.0002448081],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00457474,0.1387004,0.5861784,0.00009498622,0.0004222497,0.0003203165,0.0001292943,0.000003342743,0.0005268418,0.00003921452,0.005561392,0.2634489],"study_design_scores_gemma":[0.2072172,0.01338505,0.7592835,0.00008078486,0.0002258373,0.0002087084,0.00008532662,0.0003182514,0.00028166,0.00009412729,0.0187293,0.00009022317],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991711,0.0005832715,0.00002513032,0.0063382,0.0005809601,0.0003750752,0.00001040975,0.000006846654,0.0003690774],"genre_scores_gemma":[0.9926847,0.001569291,0.003343838,0.001106162,0.0008824282,0.000009096997,0.000005540078,0.00001814962,0.0003807997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2633587,"threshold_uncertainty_score":0.5012,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2885107163","doi":"10.1200/jco.2018.79.1483","title":"Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":978,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Hazard ratio; Surgery; Esophagectomy; Clinical endpoint; Radiation therapy; Chemoradiotherapy; Esophagus; Neoadjuvant therapy; Neutropenia; Leukopenia; Phases of clinical research; Esophageal cancer; Gastroenterology; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1956553790038129,"gpt":0.5140244621430774,"spread":0.3183690831392645,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01717605,0.0003837644,0.007265849,0.0001641942,0.0001453522,0.00003082111,0.0006924041,0.000591922,0.0002915264],"category_scores_gemma":[0.02140357,0.0002272587,0.002939117,0.0002910256,0.001488181,0.0001985903,0.0001689074,0.001145615,0.00001062996],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003297777,"about_ca_system_score_gemma":0.007008074,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009813041,"about_ca_topic_score_gemma":0.00006466891,"domain_scores_codex":[0.9886649,0.002386815,0.006822989,0.0005410131,0.0008830409,0.0007012707],"domain_scores_gemma":[0.9421736,0.04957071,0.005252742,0.0006919703,0.001350333,0.0009606496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.821167,0.021848,0.004913137,0.00005818936,0.0008048254,0.0005085515,0.00004017821,4.92597e-7,0.00007800465,0.000003460702,0.03965347,0.1109247],"study_design_scores_gemma":[0.9212268,0.06837375,0.0006842091,0.0001154633,0.001109905,0.00006024121,0.00003949492,0.0003315619,0.003874885,0.00004420269,0.003967355,0.0001721093],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9632571,0.0175452,0.0004604654,0.004688186,0.009289654,0.004540813,0.00005397329,0.00001234564,0.0001522793],"genre_scores_gemma":[0.9903451,0.001753934,0.002472232,0.001785002,0.002969883,0.0001541808,0.00001778602,0.00006137607,0.0004405234],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1107526,"threshold_uncertainty_score":0.9986213,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159862107","doi":"10.1200/jco.2011.41.0985","title":"Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":973,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Terry Fox Foundation; Michael Smith Health Research BC","keywords":"Vincristine; Medicine; Chromosomal translocation; International Prognostic Index; Immunohistochemistry; Rituximab; Lymphoma; Cyclophosphamide; Prednisone; Diffuse large B-cell lymphoma; Cancer research; CHOP; Internal medicine; Oncology; Cohort; Immunophenotyping; Pathology; Chemotherapy; Immunology; Flow cytometry; Biology; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.04353290157636887,"gpt":0.3813756691600561,"spread":0.3378427675836872,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00113866,0.0002033415,0.001817267,0.0001242474,0.00003212312,0.000006342521,0.00006476943,0.0002911844,0.00002415892],"category_scores_gemma":[0.0005330514,0.0001197746,0.0001419042,0.0001130709,0.0002224452,0.000137757,0.0000766683,0.0002463694,0.000002316991],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001969788,"about_ca_system_score_gemma":0.0004556659,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005487232,"about_ca_topic_score_gemma":0.0000306391,"domain_scores_codex":[0.9972656,0.0002626405,0.001662331,0.0002001783,0.0002873566,0.0003218453],"domain_scores_gemma":[0.9964409,0.001427441,0.001260834,0.0001563187,0.0001885627,0.00052597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004259559,0.04265846,0.91596,0.0001051148,0.0001456937,0.0003727913,0.0002775052,4.252949e-7,0.0003346579,0.0000577551,0.0005701532,0.03525792],"study_design_scores_gemma":[0.1674097,0.01219377,0.8097914,0.0004038129,0.0004549568,0.0004354477,0.0001697082,0.00004047941,0.003333733,0.00001196459,0.005649601,0.0001054084],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886658,0.009759297,0.0000260028,0.0004639786,0.0002325973,0.0002844362,0.00001526327,0.000006347916,0.0005462398],"genre_scores_gemma":[0.9941347,0.004234363,0.001007127,0.0003142824,0.0002230341,0.000009576138,0.000005179845,0.00001695737,0.00005480508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1631501,"threshold_uncertainty_score":0.4884267,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387865238","doi":"10.1200/jco.23.02005","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":931,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Takeda Oncology; Genentech; Menarini Group; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Jounce Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; AstraZeneca; Novocure; Eisai Canada; Cholangiocarcinoma Foundation; F. Hoffmann-La Roche; Taiho Pharmaceutical; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Mersana Therapeutics; Karyopharm Therapeutics; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Trastuzumab; Immunohistochemistry; Clinical endpoint; Gastroenterology; Oncology; Surgery; Cancer; Breast cancer; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.161277714946747,"gpt":0.5034432526818972,"spread":0.3421655377351502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007059278,0.0001664692,0.001700326,0.000167143,0.00009474322,0.00001287921,0.0003003432,0.0002449512,0.00004101475],"category_scores_gemma":[0.01488761,0.00009589279,0.0001704557,0.0004179098,0.0006147417,0.00009530571,0.0001790846,0.001662315,0.000003868881],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002460058,"about_ca_system_score_gemma":0.003319332,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001045484,"about_ca_topic_score_gemma":0.00005471205,"domain_scores_codex":[0.9939156,0.001115619,0.003403601,0.0003030246,0.0008799923,0.0003821166],"domain_scores_gemma":[0.9861416,0.01095005,0.001793298,0.0003393481,0.0004059618,0.0003697439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6577554,0.006936722,0.04236623,0.00004124009,0.0002270943,0.0005646164,0.0008850804,0.00004609078,0.0002696314,0.000002465625,0.003233599,0.2876719],"study_design_scores_gemma":[0.316135,0.06138084,0.6166926,0.001022474,0.0001291059,0.00002178515,0.0001475706,0.00007495884,0.00007253753,0.00006735818,0.004169741,0.00008599097],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931667,0.0001142973,0.0000195375,0.005025611,0.0004087797,0.0007727908,0.00005661087,0.00001174414,0.0004239492],"genre_scores_gemma":[0.9968565,0.0002679252,0.001253203,0.0004551395,0.001068042,0.000006140217,0.0000262008,0.00002781368,0.00003901472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5743263,"threshold_uncertainty_score":0.9934104,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2018038855","doi":"10.1200/jco.2006.09.5281","title":"Palliative Radiotherapy Trials for Bone Metastases: A Systematic Review","year":2007,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"Management of metastatic bone disease","field":"Medicine","cited_by":909,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Randomized controlled trial; Meta-analysis; Radiation therapy; Odds ratio; Internal medicine; Palliative care; Forest plot; Pathological; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.6544507210468016,"gpt":0.6580509111508396,"spread":0.003600190104038004,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.1176763,0.0006446686,0.04740421,0.0005914652,0.00003678564,0.00002057323,0.0005135049,0.0007338672,0.000497012],"category_scores_gemma":[0.1684202,0.0003517432,0.01281923,0.0004315196,0.0001797845,0.0000884367,0.00005529113,0.001528846,0.00004146445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004669106,"about_ca_system_score_gemma":0.005110273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":8.634136e-7,"about_ca_topic_score_gemma":8.782041e-7,"domain_scores_codex":[0.9637218,0.009441192,0.02482755,0.0004528059,0.001111933,0.0004446821],"domain_scores_gemma":[0.8949015,0.06130409,0.04050424,0.0008947753,0.001344877,0.001050532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007183108,0.00105698,3.823256e-7,0.554716,0.009146311,0.0007372105,0.000005682569,2.832795e-8,8.40389e-9,0.0001128571,0.02923208,0.4042742],"study_design_scores_gemma":[0.004318795,0.004195886,7.839786e-7,0.3646241,0.1019903,0.000228049,0.00001495258,0.000001826445,1.090579e-8,0.00005187701,0.5244325,0.0001409371],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[1.626393e-7,0.9756763,0.007892134,0.001780462,0.001643976,0.01251691,0.00009587224,0.00001435337,0.0003798112],"genre_scores_gemma":[8.84131e-8,0.9544168,0.03221427,0.01009199,0.001812017,0.0003078115,0.00005988004,0.00009013075,0.001007082],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4952004,"threshold_uncertainty_score":0.9998934,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2155012968","doi":"10.1200/jco.2008.16.9847","title":"Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":908,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CancerCare Manitoba","funders":"National Cancer Institute","keywords":"Medicine; Bevacizumab; Internal medicine; Renal cell carcinoma; Clinical endpoint; Hazard ratio; Gastroenterology; Proteinuria; Oncology; Surgery; Randomized controlled trial; Chemotherapy; Confidence interval; Kidney","retraction":null,"screen_n_in":null,"score":{"opus":0.0995623420053774,"gpt":0.3685206473544246,"spread":0.2689583053490472,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00102837,0.0004339836,0.002862043,0.0003688506,0.00006003113,0.00001194989,0.0003050606,0.000264872,0.0001884634],"category_scores_gemma":[0.0001678828,0.0002577673,0.0004058017,0.0002714891,0.0004476226,0.0001944158,0.00006467792,0.001547481,0.00002555965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001223235,"about_ca_system_score_gemma":0.002030297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001792743,"about_ca_topic_score_gemma":0.0002837829,"domain_scores_codex":[0.9945446,0.0007490009,0.002909709,0.0004609263,0.0008225758,0.0005132266],"domain_scores_gemma":[0.9953772,0.0009734219,0.001958423,0.000435883,0.0006257118,0.0006293469],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2151031,0.009415489,0.7473314,0.0000980348,0.0009463314,0.009744462,0.001417243,0.0004485412,0.0001451931,0.0000052102,0.002773887,0.01257114],"study_design_scores_gemma":[0.08819126,0.1456011,0.7599397,0.0002485718,0.0007093165,0.001114613,0.0002208111,0.000223484,0.0007426508,0.00002194496,0.002698076,0.0002884491],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955536,0.000566385,0.0004151025,0.001020188,0.0003777134,0.0007097503,0.000009431445,0.0000130085,0.001334855],"genre_scores_gemma":[0.9920803,0.0001240199,0.006304625,0.000798632,0.0002777983,0.0000160232,0.00002901718,0.00006228898,0.0003073386],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1361856,"threshold_uncertainty_score":0.9999875,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162605078","doi":"10.1200/jco.2004.06.082","title":"Abbreviated Course of Radiation Therapy in Older Patients With Glioblastoma Multiforme: A Prospective Randomized Clinical Trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":895,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Radiation therapy; Randomization; Quality of life (healthcare); Internal medicine; Wilcoxon signed-rank test; Glioblastoma; Clinical endpoint; Randomized controlled trial; Survival analysis; Surgery; Prospective cohort study; Mann–Whitney U test","retraction":null,"screen_n_in":null,"score":{"opus":0.04764455615456314,"gpt":0.4428320914777188,"spread":0.3951875353231556,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005753488,0.0001810313,0.00334328,0.0001778043,0.00001896205,0.000005304576,0.00009363412,0.0003987755,0.00005215076],"category_scores_gemma":[0.005290081,0.0000953875,0.0008859016,0.0002501283,0.0003434326,0.0001112993,0.00001444084,0.0006714412,0.000004398133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002025163,"about_ca_system_score_gemma":0.001580011,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002231078,"about_ca_topic_score_gemma":0.00005440287,"domain_scores_codex":[0.9940295,0.001002597,0.004144452,0.0002140006,0.0004138877,0.000195555],"domain_scores_gemma":[0.9908634,0.004419938,0.003527025,0.0001706102,0.0007607966,0.0002581978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5461571,0.02453425,0.3412479,0.000005218936,0.0007482058,0.0001045236,0.0001071278,0.00002032847,0.0000019558,0.00002425873,0.0000547966,0.08699428],"study_design_scores_gemma":[0.5099235,0.0394351,0.4498546,0.0001177649,0.0002688116,0.00001014517,0.00001876858,0.00001298923,0.00009275085,0.0001033157,0.0001174771,0.00004469106],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946068,0.0003672028,0.00004543316,0.001751698,0.0007882488,0.002343137,0.000004070737,0.000006041615,0.00008738181],"genre_scores_gemma":[0.9972175,0.00111222,0.000720225,0.0004339958,0.0004479405,0.00004238249,0.000005276129,0.00001680094,0.000003644646],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1086067,"threshold_uncertainty_score":0.6333104,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}